Prelude Capital Management’s Dr. Reddy's Laboratories RDY Stock Holding History

Prelude Capital Management’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-38,500	Closed	-$508K	–	1293
2025 Q1	$508K	Sell	38,500 -1,336	-3%	-$18.4K	0.04%	513
2024 Q4	$629K	Sell	39,836 -16,979	-30%	-$255K	0.04%	505
2024 Q3	$903K	Buy	56,815 +315	+0.6%	+$5.07K	0.05%	415
2024 Q2	$861K	Sell	56,500 -18,500	-25%	-$265K	0.06%	353
2024 Q1	$1.1M	Hold	75,000	–	–	0.06%	373
2023 Q4	$1.04M	Hold	75,000	–	–	0.07%	294
2023 Q3	$1M	Hold	75,000	–	–	0.07%	302
2023 Q2	$947K	Hold	75,000	–	–	0.06%	315
2023 Q1	$854K	Sell	75,000 -380	-0.5%	-$4.1K	0.05%	337
2022 Q4	$780K	Buy	75,380 +380	+0.5%	+$4.1K	0.04%	432
2022 Q3	$785K	Buy	75,000 +18,320	+32%	+$195K	0.03%	493
2022 Q2	$628K	Sell	56,680 -18,320	-24%	-$199K	0.02%	694
2022 Q1	$836K	Buy	75,000 +24,500	+49%	+$278K	0.02%	657
2021 Q4	$661K	Sell	50,500 -15,500	-23%	-$195K	0.02%	852
2021 Q3	$860K	Hold	66,000	–	–	0.02%	629
2021 Q2	$970K	Hold	66,000	–	–	0.03%	629
2021 Q1	$810K	Hold	66,000	–	–	0.02%	686
2020 Q4	$941K	Hold	66,000	–	–	0.02%	492
2020 Q3	$918K	Hold	66,000	–	–	0.04%	289
2020 Q2	$700K	Buy	+66,000	New	+$671K	0.04%	397

Other funds holding RDY

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

AIM

Aikya Investment Management London, United Kingdom $341M AUM 28.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Prelude Capital Management's RDY Position: Q2 2025 in Review

Prelude Capital Management sold out of Dr. Reddy's Laboratories (RDY) in Q2 2025, closing a stake of 38,500 shares — an estimated $508K sold.

Prelude Capital Management first reported a position in RDY in Q2 2020 and held it in 20 quarters. The position peaked at $1.1M in Q1 2024. 243 funds tracked by Wall St. Rank hold RDY as of Q2 2025.

Prelude Capital Management reported no remaining Dr. Reddy's Laboratories position as of Q2 2025 after selling out during the quarter.
Prelude Capital Management sold 38,500 Dr. Reddy's Laboratories shares in Q2 2025, an estimated $508K.
Prelude Capital Management first reported a position in Dr. Reddy's Laboratories in Q2 2020 and held it in 20 quarters.
Prelude Capital Management's Dr. Reddy's Laboratories position peaked at $1.1M in Q1 2024.
243 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2025.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.